NDA 220425 · Elevar
Lyrfigtu
Lirafugratinib Hydrochloride · Oral
NovelPriority reviewOrphanCDER novel approval, Sep 23, 2026: To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Sep 23, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
Therapeutic areas: Oncology · Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 23, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
2 products under this application
- LYRFIGTU · LIRAFUGRATINIB HYDROCHLORIDE EQ 20MG BASE · CAPSULE, ORAL · Prescription
- LYRFIGTU · LIRAFUGRATINIB HYDROCHLORIDE EQ 30MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lirafugratinib" as an intervention, any sponsor and status, largest first.
Elevar TherapeuticsIndustry
NCT07359820 · 30 participants (planned) · Start Jun 4, 2026 · Primary completion Sep 2027
Drug: Lirafugratinib · For: FGFR2 Gene Fusion/Rearrangement; Other Solid Tumors, Adult
Sites: Phoenix, Arizona; Jacksonville, Florida; Tampa, Florida · 19 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.
Facchinetti F, Hollebecque A, Barbé R, et al. · Clin Cancer Res 2026 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Elevar
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.